Clinical trial
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in…
NCT00053508 · Sanofi Pasteur, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00053508 |
|---|---|
| Title | Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination |
| Official title | The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smallpox |
| Intervention type | Biological |
| Interventions | ACAM1000, vaccinia virus (calf lymph) smallpox vaccine: Dryvax |
| Enrollment | 274 |
| Start date | Sep 1, 2002 |
| Primary completion | Mar 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | Jan 31, 2003 |
| Last update posted | Jan 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: